Patents
Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
Patent Number: 7,342,110One of the major technological advances that allowed for the characterization and use of stem cells was the development of defined monoclonal antibodies that repeatedly attached to markers on stem cells. For example, the patents covering the original hematopoietic stem cells used monoclonal antibodies to actually identify the cell...
Inventors: Hoffee; Mary G. (Brookline, MA), Tavares; Daniel (Natick, MA), Lutz; Robert J. (Wayland, MA)
Assignee: Immunogen Inc. (Cambridge, MA)
Date of First Priority Issue: Wednesday November 5th, 2003
Pine cone extracts and uses thereof
Patent Number: 7,338,676Dendritic cells are the most potent stimulators of the immune system, having the unique ability to activate naive T cells. Thus dendritic cells are of great interest in terms of immune stimulatory approaches for treatment of cancer and viral diseases. On the flip side of the coin, dendritic cells are known to have the ability of...
Inventors: Tanaka; Akiko (St. Petersburg, FL), Bradley; William Guy (St. Petersburg, FL)
Assignee: Tampa Bay Research Institute (St. Petersburg, FL)
Date of First Priority Issue: Wednesday September 26th, 2001
Methods for treating a patient undergoing chemotherapy
Patent Number: 7,338,938The current patent covers the use of a peptide derived from angiotensin I for stimulation of hematopoiesis after insult to the blood making system of a host. Specifically, the patent addresses the hematopoietic insult of chemotherapy. Since many types of chemotherapeutic agents kill proliferating cells, the hematopoietic system is often injured as a consequence of administration of these agents...
Inventors: Rodgers; Kathleen (Long Beach, CA), diZerega; Gere (Los Angeles, CA)
Assignee: University of Southern California (Los Angeles, CA)
Date of First Priority Issue: Friday January 23rd, 1998
Connective tissue substitutes, method of preparation and uses thereof
Patent Number: 7,335,230One of the areas in which regenerative medicine has caused the most advancement is in repair of connective tissue injuries. The current patent addresses this area. Specifically, the patent covers an object that can be implanted and used as a substitute for a connective tissue. The objected is made with a pair of bone anchors, with at least one filament connecting the bone achors at their...
Inventors: Goulet; Francine (Sainte-Foy, CA), Rancourt; Denis (Levis, CA), Cloutier; Rejean (Sillery, CA), Tremblay; Julie (Beauport, CA), Auger; Francois A. (Sillery, CA), Normand; Albert (Sainte-Foy, CA), German; Lucie (St-Augustin, CA), Lamontagne; Jean (St-Augus
Assignee: Universite de Montreal (Montreal, CA)
Date of First Priority Issue: Friday November 24th, 2000
Method for stimulating hair follicle cell proliferation
Patent Number: 7,335,641The current patent covers ways of induce proliferation of hair follicle cells through administration of a specific protein or variants of it. The protein is called "hair follicle growth factor" or "HFGF". HFGF is considered to be an allelic form of keratinocyte growth factor-2 (KGF-2) wherein HFGF has a glutamic acid residue (Glu) at position 87, whereas KGF-2 has a lysine residue (Lys) at this...
Inventors: Kim; Soogyun (Chungdam-dong, Gangnam-gu, Seoul, KR), Jang; Hyun-Jun (Youngdeungpo-du, Seoul, KR)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday May 24th, 2001
Use of erythropoietin for the preventive or curative treatment of cardiac failure
Patent Number: 7,335,490The use of erythropoietin for non-hematopoietic purposes has been increasing in the last couple of years. One obvious example is the Canadian company Stem Cell Therapeutics (sss.v) which is using erythropoietin together with human chorionic gonadotropin for treatment of patients post-stroke. Other uses of erthrypoietin include direct
Assignee: Crucell Holland B.V. (Leiden, NL); Stichting Klinische Farmacologie Groningen (Groningen, NL)
Date of First Priority Issue: Wednesday January 9th, 2002
Compositions and treatments for myelosuppression by ex vivo activated immune cells
Patent Number: 7,332,158Failure/suppression of the hematopoietic can be a deadly consequence of over-aggressive administration of chemotherapeutics/radiotherapy. The global market for agents that stimulate hematopoiesis, particularly granulopoiesis is in the billions of dollars per year, as witnessed by the success of Amgen’s Neuopgen and Neulasta products. The current patent teaches a novel, and arguably more...
Inventors: Yang; Demao (Mountain View, CA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Wednesday May 29th, 2002
Hematopoietic stem cells treated by in vitro fucosylation and methods of use
Patent Number: 7,332,334On of the interesting methods of manipulating stem cells is to increase their ability to “go where they are suppose to”. For example, it is known that when bone marrow or cord blood hematopoietic stem cells are injected intravenously into an irradiated recipient, the cells selectively home to the bone marrow and if enough cells migrate appropriately, hematopoietic reconstitution occurs. Some...
Inventors: Xia; Lijun (Edmond, OK), McEver; Rodger P. (Oklahoma City, OK)
Assignee: Oklahoma Medical Research Foundation (Oklahoma City, OK)
Date of First Priority Issue: Friday April 18th, 2003
Methods for inducing differentiation of pluripotent cells
Patent Number: 7,332,336Mesenchymal stem cells are originally thought of as bone marrow derived, adherent cells, that have the ability to differentiate into a variety of tissues. Initial studies demonstrated that mesenchymal stem cells can differentiate into bone, cartilage, fat and muscle. These cells possess a very strong possibility for commercialization and therapeutics development since they can be administered to...
Inventors: Ochiya; Takahiro (Chuo-ku, JP), Teratani; Takumi (Matsudo, JP)
Assignee: Effector Cell Institute, Inc. (Meguro-Ku, JP)
Date of First Priority Issue: Saturday April 19th, 2003
Fish produced by nuclear transfer from cultured cells
Patent Number: 7,332,647One may notice that many of the patents in the StemCellPatents.com database direct their claims towards "mammals" here is one exception. The current patent is directed towards cloning of fish. The inventors state that nuclear transfer in fish was actually performed since the 1960s, however despite much work in the area, this is the first time that cultured cells are used as nucleus donors. This...
Inventors: Lin; Shuo (Los Angeles, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Tuesday June 11th, 2002